Neumoloxía
Servizo
Corporació Sanitària Parc Taulí
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Corporació Sanitària Parc Taulí (14)
2023
-
Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study
Drugs, Vol. 83, Núm. 12, pp. 1111-1123
-
Potential impact of mepolizumab in stepping down anti-osteporotic treatment in corticosteroid-dependent asthma
Frontiers in Pharmacology, Vol. 14
-
Treatment Patterns of Monoclonal Antibodies in Patients With Severe Uncontrolled Asthma Treated by Pulmonologists in Spain
Open Respiratory Archives, Vol. 5, Núm. 3
2022
-
Consensus document for severe asthma in adults. 2022 update
Open Respiratory Archives, Vol. 4, Núm. 3
-
Monoclonal antibody treatment for severe uncontrolled asthma in Spain: analytical map
Journal of Asthma, Vol. 59, Núm. 10, pp. 1997-2007
2021
-
Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study (Drugs, (2021), 81, 15, (1763-1774), 10.1007/s40265-021-01597-9)
Drugs
-
REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study
Drugs, Vol. 81, Núm. 15, pp. 1763-1774
2020
-
Evaluation of the Integrated Tuberculosis Research Program Sponsored by the Spanish Society of Pulmonology and Thoracic Surgery: 11 Years on
Archivos de Bronconeumologia, Vol. 56, Núm. 8, pp. 483-492
-
Factors Associated With Extrapulmonary Tuberculosis in Spain and Its Distribution in Immigrant Population
Open Respiratory Archives, Vol. 2, Núm. 3, pp. 119-126
2019
-
Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study
Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 7, pp. 2277-2283.e2
2017
-
Asthma outcomes improve with continuous positive airway pressure for obstructive sleep apnea
Allergy: European Journal of Allergy and Clinical Immunology, Vol. 72, Núm. 5, pp. 802-812
2016
-
Factors associated with fatality during the intensive phase of anti-tuberculosis treatment
PLoS ONE, Vol. 11, Núm. 8
-
Spanish Compliance With Guidelines for Prescribing Four Drugs in the Intensive Phase of Standard Tuberculosis Treatment
Archivos de Bronconeumologia, Vol. 52, Núm. 5, pp. 262-268